Protocol Ledger

NCT07242300 · Phase III · RECRUITING

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

Interventional Phase III clinical trial protocol NCT07242300 sponsored by JHM BioPharma (Tonghua) Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-11 Enrollment: 207 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07242300
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)207 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07242300
Protocol FieldVerified Registry Value
NCT IdentifierNCT07242300
Consolidated Lead SponsorJHM BioPharma (Tonghua) Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment207 participants (ESTIMATED)
Registered Start Date2025-12-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07242300
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital of Bengbu Medical CollegeBengbu, ChinaOpen Hospital Dossier ->
Beijing Tsinghua Changgung HospitalBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI